Clinical experience with cefotaxime in obstetric and gynecologic infections.

D. L. Hemsell, F. G. Cunningham, C. M. Nolan, T. T. Miller

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Infections in the upper genital tract continue to be one of the leading causes of serious morbidity for obstetric and gynecologic patients. The polymicrobial, mixed aerobic and anaerobic isolates recovered from women with such infections demand broad-spectrum antimicrobial activity. In the past, combination therapy has been given in order to attain this coverage. In a multicenter open study, cefotaxime was used for treatment of endomyometritis after cesarean section, pelvic cellulitis after hysterectomy, and acute pelvic inflammatory disease. The drug effected a clinical cure in 93% of 104 women. In a randomized comparative study conducted at one center, cefotaxime cured 97% of 36 cases of post-cesarean section endomyometritis; clindamyclin plus gentamicin cured 94% of 18 cases of the same infection. There was no evidence of significant alteration in hematopoietic, hepatic, or renal function with either regimen. Cefotaxime appears to be a safe, extremely effective antimicrobial drug that is ideally suited for single-agent treatment of serious soft-tissue pelvic infections in obstetric or gynecologic patients.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume4 Suppl
StatePublished - Sep 1982

Fingerprint

Cefotaxime
Obstetrics
Endometritis
Cesarean Section
Parametritis
Infection
Pelvic Infection
Pelvic Inflammatory Disease
Soft Tissue Infections
Gentamicins
Hysterectomy
Pharmaceutical Preparations
Multicenter Studies
Therapeutics
Morbidity
Kidney
Liver

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Clinical experience with cefotaxime in obstetric and gynecologic infections. / Hemsell, D. L.; Cunningham, F. G.; Nolan, C. M.; Miller, T. T.

In: Reviews of Infectious Diseases, Vol. 4 Suppl, 09.1982.

Research output: Contribution to journalArticle

@article{acdfc57693e841a1bcf0523fe7193fc1,
title = "Clinical experience with cefotaxime in obstetric and gynecologic infections.",
abstract = "Infections in the upper genital tract continue to be one of the leading causes of serious morbidity for obstetric and gynecologic patients. The polymicrobial, mixed aerobic and anaerobic isolates recovered from women with such infections demand broad-spectrum antimicrobial activity. In the past, combination therapy has been given in order to attain this coverage. In a multicenter open study, cefotaxime was used for treatment of endomyometritis after cesarean section, pelvic cellulitis after hysterectomy, and acute pelvic inflammatory disease. The drug effected a clinical cure in 93{\%} of 104 women. In a randomized comparative study conducted at one center, cefotaxime cured 97{\%} of 36 cases of post-cesarean section endomyometritis; clindamyclin plus gentamicin cured 94{\%} of 18 cases of the same infection. There was no evidence of significant alteration in hematopoietic, hepatic, or renal function with either regimen. Cefotaxime appears to be a safe, extremely effective antimicrobial drug that is ideally suited for single-agent treatment of serious soft-tissue pelvic infections in obstetric or gynecologic patients.",
author = "Hemsell, {D. L.} and Cunningham, {F. G.} and Nolan, {C. M.} and Miller, {T. T.}",
year = "1982",
month = "9",
language = "English (US)",
volume = "4 Suppl",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Clinical experience with cefotaxime in obstetric and gynecologic infections.

AU - Hemsell, D. L.

AU - Cunningham, F. G.

AU - Nolan, C. M.

AU - Miller, T. T.

PY - 1982/9

Y1 - 1982/9

N2 - Infections in the upper genital tract continue to be one of the leading causes of serious morbidity for obstetric and gynecologic patients. The polymicrobial, mixed aerobic and anaerobic isolates recovered from women with such infections demand broad-spectrum antimicrobial activity. In the past, combination therapy has been given in order to attain this coverage. In a multicenter open study, cefotaxime was used for treatment of endomyometritis after cesarean section, pelvic cellulitis after hysterectomy, and acute pelvic inflammatory disease. The drug effected a clinical cure in 93% of 104 women. In a randomized comparative study conducted at one center, cefotaxime cured 97% of 36 cases of post-cesarean section endomyometritis; clindamyclin plus gentamicin cured 94% of 18 cases of the same infection. There was no evidence of significant alteration in hematopoietic, hepatic, or renal function with either regimen. Cefotaxime appears to be a safe, extremely effective antimicrobial drug that is ideally suited for single-agent treatment of serious soft-tissue pelvic infections in obstetric or gynecologic patients.

AB - Infections in the upper genital tract continue to be one of the leading causes of serious morbidity for obstetric and gynecologic patients. The polymicrobial, mixed aerobic and anaerobic isolates recovered from women with such infections demand broad-spectrum antimicrobial activity. In the past, combination therapy has been given in order to attain this coverage. In a multicenter open study, cefotaxime was used for treatment of endomyometritis after cesarean section, pelvic cellulitis after hysterectomy, and acute pelvic inflammatory disease. The drug effected a clinical cure in 93% of 104 women. In a randomized comparative study conducted at one center, cefotaxime cured 97% of 36 cases of post-cesarean section endomyometritis; clindamyclin plus gentamicin cured 94% of 18 cases of the same infection. There was no evidence of significant alteration in hematopoietic, hepatic, or renal function with either regimen. Cefotaxime appears to be a safe, extremely effective antimicrobial drug that is ideally suited for single-agent treatment of serious soft-tissue pelvic infections in obstetric or gynecologic patients.

UR - http://www.scopus.com/inward/record.url?scp=0020181338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020181338&partnerID=8YFLogxK

M3 - Article

C2 - 6294795

AN - SCOPUS:0020181338

VL - 4 Suppl

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -